New drug approved for Chronic Fatigue Syndrome, as mystery disease causes come into focus

| August 25, 2016
e dc c e cb e
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

On August 23, a new drug, rintatolimod, which has the U.S. trade name Ampligen, became the first drug approved anywhere in the world to treat the mystifying condition known as Chronic Fatigue Syndrome. It was approved for use in Argentina but has not yet been approved in the United States. According to the Philadelphia-based company, Hemisphere Biopharma,that developed the drug, “there are no other products in the pipeline for approval, worldwide, for this debilitating disease.”

This is considered validation of claims by CFS sufferers that the condition is physical illness rather than a psychological one.

One of the hardest things to do in science is to pin-down confirmatory results of something not happening—or “proving a negative.” So for example, if you have a rare condition in the general public and you test out a treatment for it and wait to see if the treatment was effective… how long do you wait? How do you know if a period of time with unnaturally-few cases (or no cases) was due to the treatment working, or just that it was very rare in the first place so you’re witnessing small variations of something that almost never happens?

Such is the case with CFS. Not only do fewer than 0.33% of the public report Chronic Fatigue Syndrome, but validating improvement in a patient with CFS is very difficult because we are trying to assess the absence of symptoms, and these symptoms are often vague, non-specific, and very fluid in nature.

So what’s the cause?

In the virology world, we try to identify the ‘causative agent’ responsible for what are oftentimes non-specific or overlapping symptoms. It’s no so different than the case with CFS, which has proven to  likewise be a slippery in pinning down. Some theorized causative agents over the past two to three decades have been Epstein-Barr virus (EBV), Human herpesvirus 6 (HHV-6), Xenotropic murine leukemia virus-related virus (XMRV), and other candidates. None has provided satisfactory evidence for a relationship with CFS.There’s conjecture as well that gut bacteria are related to CFS. There’s even a healthy cottage industry mesmerized with the concept of ‘adrenal fatigue’, which boosts rates of self-diagnosis and confounds the measurement and treatment of real Chronic Fatigue Syndrome.

A new study in published in Microbiome has identified what might be a bacterial biomarker for the disease Researchers recruited 48 people reporting CFS symptoms and 39 healthy controls. They analyzed the bacteria species in their stool and searched for markers of inflammation in their blood.

The stool samples of those with CFS. had significantly lower diversity of species compared with the healthy people, which is also typical of inflammatory bowel disease. The scientists also discovered higher blood levels of lipopolysaccharides, inflammatory molecules that may indicate that bacteria have moved from the gut into the bloodstream, where they can produce various symptoms of disease.

Related article:  Meet the Press Online video debate: Should GMO foods be labeled?

“There’s a biological difference between people with C.F.S. and healthy people,” said the senior author of the study, Cornell University molecular biologist Maureen Hanson. “The long-lasting idea that it’s a psychological illness should be abandoned.”

Recent research published in the Journal of Nuclear Medicine using positron-emission tomography has lent evidence for inflammation in certain brain regions as an associated factor of CFS. Specifically, the researchers found inflammation marker levels (translocator protein, nondisplaceable binding potential (BPND) “in the cingulate cortex, hippocampus, amygdala, thalamus, midbrain, and pons were 45%–199% higher in CFS/ME patients than in healthy controls.” The inflammation markers positively correlated with cognitive impairment (when found in the amygdala and thalamus), positively correlated with pain (when found in the thalamus and cingulate cortex), and positively correlated with depression (when found in the hippocampus). However with such a small sample size (10 controls, 9 patients) the best that can be claimed for these results is that there may be an association, and it’s a new avenue to research for further exploration to see if continued refined results yield the same conclusions and support the same hypothesis.

As I note previously in a post about the neurobiology and genetics behind addiction, in addition to neurotransmitter receptor density, there is also potentially a link between reduced neurotransmitter quantity and reduced serotonin transporters in those patients suffering with Chronic Fatigue Syndrome. This could indicate an association between genetics, brain structural and functional changes, and CFS.

What we don’t know here still outweighs what we do know. Working against us are the low probabilities of having CFS, and even then–standardizing on a measure of how one knows whether he or she has Chronic Fatigue. The yardstick by which one measures CFS clinical symptomology has very little reliability, meaning that we can’t even know if what we’re looking at is getting better or worse until we know what it is we’re trying to measure.

What is clear is that viruses and our human genes tend to co-mingle and cause structural and functional changes. As we learn more, it proves to be a complicated interrelationship.

Ben Locwin, Ph.D., M.B.A., M.S. is a contributor to the Genetic Literacy Project and is an author of a wide variety of scientific articles in books and magazines. He is an expert contact for the American Association of Pharmaceutical Scientists (AAPS), a member in the American Statistical Association (ASA), and a consultant in the biological sciences, pharmaceutical, psychological industries and for academia. Follow him at @BenLocwin.

The GLP featured this article to reflect the diversity of news, opinion and analysis. The viewpoint is the author’s own. The GLP’s goal is to stimulate constructive discourse on challenging science issues.

Outbreak Daily Digest
Biotech Facts & Fallacies
Talking Biotech
Genetics Unzipped
a a b b a f ac a

Video: Death by COVID: The projected grim toll in historical context

The latest statistics, as of July 10, show COVID-19-related deaths in U.S. are just under 1,000 per day nationally, which is ...
mag insects image superjumbo v

Disaster interrupted: Which farming system better preserves insect populations: Organic or conventional?

A three-year run of fragmentary Armageddon-like studies had primed the journalism pumps and settled the media framing about the future ...
dead bee desolate city

Are we facing an ‘Insect Apocalypse’ caused by ‘intensive, industrial’ farming and agricultural chemicals? The media say yes; Science says ‘no’

The media call it the “Insect Apocalypse”. In the past three years, the phrase has become an accepted truth of ...
types of oak trees

Infographic: Power of evolution? How oak trees came to dominate North American forests

Over the course of some 56 million years, oaks, which all belong to the genus Quercus, evolved from a single undifferentiated ...
biotechnology worker x

Can GMOs rescue threatened plants and crops?

Some scientists and ecologists argue that humans are in the midst of an "extinction crisis" — the sixth wave of ...
food globe x

Are GMOs necessary to feed the world?

Experts estimate that agricultural production needs to roughly double in the coming decades. How can that be achieved? ...
eating gmo corn on the cob x

Are GMOs safe?

In 2015, 15 scientists and activists issued a statement, "No Scientific consensus on GMO safety," in the journal Environmental Sciences ...
Screen Shot at PM

Charles Benbrook: Agricultural economist and consultant for the organic industry and anti-biotechnology advocacy groups

Independent scientists rip Benbrook's co-authored commentary in New England Journal calling for reassessment of dangers of all GMO crops and herbicides ...
Screen Shot at PM

ETC Group: ‘Extreme’ biotechnology critic campaigns against synthetic biology and other forms of ‘extreme genetic engineering’

The ETC Group is an international environmental non-governmental organization (NGO) based in Canada whose stated purpose is to monitor "the impact of emerging technologies and ...
Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend